Cipla (Results Review 2QFY22): In-line quarter; upbeat on outlook. Maintain BUY
The US business witnessed improved traction and grew ~1% QoQ, led by market share gains in Albuterol and Arformoterol. Its respiratory pipeline in...
65 Views
Cipla: Strong Q1 Led by Core Therapies, Covid Portfolio
Indian branded formulations business accounts for ~40% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac,...
116 Views
HSIE Results Daily: Godrej Consumers, Cipla, GAIL, Gujarat Gas, Hindustan Petroleum Corporation,...
Aditya Birla Capital: As outlined in our Initiation note, Aditya Birla Capital (ABCL) continues on its journey towards a credible makeover, driving...
272 Views
Adding peptide injectables to Respiratory pipeline for US market
Adding peptide injectables to Respiratory pipeline for US market Motilal Oswal values your support in the Asiamoney Brokers Poll 2021...
256 Views